Berlin-(Business):™E Pharma NV (Euronext Growth Paris: AL™E), A clinical-stage biotechnology company focused on developing novel therapies to treat cancer by targeting the tumor environ- ment (E™), today announced that an abstract including results from the NOX-A12 GLORIA Phase 1/2 trial in first-line brain cancer (glioblastoma) has been selected for presentation at the European Society for Medical Oncology (ESMO) Congress Scheduled to be held in Barcelona, Spain, from 13 to 17 September 2024.
The oral presentation will provide further analysis of dual NOX-A12 inhibition and bevacizumab in glioblastoma in the expansion arm of the GLORIA Phase 1/2 trial. The full abstract will be published online via the ESMO Congress website at 00:05 am CEST on Monday 9 September 2024. It will be available simultaneously on ™E-Pharma website.
Dual inhibition of angiogenesis after radiation in glioblastoma: results from the phase 1/2 GLORIA trial
Presenter: doctor. Frank A. Giordano, Head of the Department of Radiation Oncology, University Medical Center Mannheim, Germany
a class: Short Oral Session: Central Nervous System Tumors
Time and date: 08.30-8.35 AM CEST, Sunday 15 September 2024
About E Pharma™
™E-Pharma A clinical-stage company focused on developing novel therapies to treat the most aggressive cancers. The company’s oncology-focused pipeline is designed to act on the tumor-environment (TEN) and cancer-immune cycle by breaking down tumor barriers to the immune system and preventing tumor repair.
You can view the original press release on businesswire.com: https://www.businesswire.com/news/home/20240716299422/en/
for more information:
™E Pharma NV
Aram Mangasarian, Ph.D., CEO
Tel. +49 (0) 30 16637082 0
investors@tmepharma.com
Investor and Media Relations:
Life Science Consultants
Guillaume van Renterghem
Tel. +41 (0) 76 735 01 31
gvanrenterghem@lifesciadvisors.com
Newcap
Arthur Rowell
Tel. +33 (0) 1 44 71 00 15
arwell@newcap.fr
Source: ™E Pharma NV